Something groundbreaking has happened in the CBD world in recent weeks, and its consequences will have a positive effect on many industries in the years to come.
In recent years, with the rise of the popularity of CBD, the FDA in the United States has taken a false caution by making statements such as, "CBD can cause liver damage" and "CBD can affect the way other medications you are taking work, including potentially serious side effects."
With little verified or official research available, the FDA very conservative when it came to CBD. They only approved one pharmaceutical-grade CBD-based drug, a drug used to treat seizures related to certain types of epilepsy.
Research on liver effects for the FDA
However, about 18 months ago, the Food and Drug Administration contacted the company Validcare, a patient-centered clinical research facility. The FDA wanted to collect safety data on CBD so they could better know how to regulate the CBD-based hemp industry.
Patrick McCarthy, CEO of Validcare, spoke about the weight and importance of the study:
“We understand the importance, importance and immediate need for CBD safety research for the FDA, the industry and the US consumer. This first of its kind, industry-led, multi-branded research required trust, collaboration, operational excellence, innovation and resilience. It demonstrates the incredible potential of decentralized clinical research to increase participant access and accelerate results - even in the most challenging of times. We are delighted that our principal investigators will continue, expand and report on this fundamental work in the coming months. Upon completion, the safety results of this study will be shared with participating brands and FDA. The researchers also plan to publish in a peer-reviewed journal. ”
From August 2020 to February 2021, Validcare conducted a survey among 839 participants. Their primary end goal of the study was to observe possible liver effects in adults when taking oral forms of hemp-derived CBD, and they wanted to do this for a minimum of 681 people for at least 60 days.
What they observed over the course of 7 months was that there was no clinical evidence of liver disease in any of the participants. According to co-researcher Jeff Lombardo PharmD, BCOP:
“We have observed mild, clinically insignificant elevations in liver function tests in less than 839 percent of consumers, regardless of age, product composition and shape, and amount consumed. Three of the 3 participants had XNUMXx normal levels of the liver enzyme ALT. These three consumers are on prescription drugs that are known to increase liver enzymes, and we're investigating whether prescription drugs or other factors contribute to these outliers. “
On further investigation, it was found that the 3 participants were already on drugs that caused higher levels of this enzyme as a side effect before the study began.
These initial results invalidate the idea that CBD can accumulate in the liver and cause liver toxicity, and make this study even more compelling with regard to safety factors for the general public.
In addition, the researchers were surprised to find that nearly 70% of the participants had some medical condition treated by medication that entered the study, and yet none of them reported an increase in side effects when using the CBD in the study. combination with their medications.
This means that the idea that CBD could interfere with "ALL" drugs in general is not necessarily true. Certainly more studies need to be completed. This remains is still an important thing to talk to your doctor about first, especially if your medication has a grapefruit warning. If your medication has such a grapefruit warning, don't take CBD. But the study's findings are unexpected and undeniably good news!